Health

Add as a preferred source on Google

Scancell Reports FDA Designation for Melanoma Candidate and Trial Results

In a kidney cancer trial, 75% of patients who developed an immune response were progression-free at six months, compared with 50% of those who did not.

Updated 2 min read
A researcher handles sample trays inside an oncology laboratory in Cambridge, United Kingdom. (AI-generated image / EconoTimes)
A researcher handles sample trays inside an oncology laboratory in Cambridge, United Kingdom. (AI-generated image / EconoTimes)

Scancell Holdings said the U.S. Food and Drug Administration granted its investigational melanoma candidate inzitagene plasmivec Regenerative Medicine Advanced Therapy designation, while a separate kidney cancer trial found longer progression-free survival among patients who developed an immune response.

Scancell plans to start a global Phase 3 trial of inzitagene plasmivec, also known as iSCIB1+, and expects to enroll the first participant in December 2026. The company said a planned Nasdaq listing in late 2026 or early 2027 is expected to help fund the study.

The designation allows closer interaction with the FDA during development. The agency says designated products may qualify for rolling or priority review or accelerated approval if they meet the relevant criteria; RMAT designation itself is not marketing approval.

In the Phase 2 ModiFY trial, 46% of 43 patients with renal cell carcinoma developed an immune response to Modi-1, Scancell reported. Six-month progression-free survival was 75% among responders and 50% among nonresponders. After 22 months of follow-up, median progression-free survival had not been reached for responders, compared with six months for nonresponders.

All 43 patients in the kidney cancer cohort received Modi-1 with ipilimumab and nivolumab. Scancell reported a 48% objective response rate and median progression-free survival of 7.8 months across the group. The comparison between responders and nonresponders shows an association; it does not establish that the immune response caused the difference in outcomes.

Scancell also reported results from its Phase 2 SCOPE melanoma trial. At 24 months, overall survival was 82% across the combined SCIB1 and iSCIB1+ groups, which included 80 patients, and 87% in the iSCIB1+ group. In the HLA-target population, 24-month progression-free survival was 65% for the combined groups and 71% for iSCIB1+. The company said it analyzed the data cut on Nov. 12, 2026.

Related articles

View all